The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms LUMEN
- 01 Sep 2024 Results published in the Clinical Nuclear Medicine
- 01 Feb 2024 Results assessing peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients, published in the Journal of Nuclear Medicine.
- 23 Sep 2022 Status changed from recruiting to completed.